Reducing a major cost burden of therapeutic cell manufacturing by selectivelyremoving toxic culture byproducts to allow recycling of media
Award amount
$224,453Program and phase
STTR · Phase IAward year
2021Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- OSSIUM HEALTH INC
- Proposal award date
- 2021-09-20
- Contract end date
- 2022-07-19
- UEI
- FFNHJ2RDRHW3
- Solicitation number
- PA20-265
- Topic code
- 400
Research abstract
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Developing a bank of purified myeloid progenitor cells as a bridging therapy for transient pancytopenia resulting from radiation injury
- A novel approach to Mesenchymal Stem Cell Transduction
- Developing a bank of purified myeloid progenitor cells as a bridging therapy for transient pancytopenia resulting from radiation injury
- A Novel and Clinically Feasible Co-therapy of Deceased Donor Bone Marrow Combined With Donor-Matched Mesenchymal Stem Cells to Establish Immune Tolerance
- Novel strategies for storage and recovery of cadaveric bone marrow stem cells
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Platform for Optimizing Yield and Quality of Therapeutic AAV Vector Manufacturing via Synthetic Helper Genes
- Ultra-low-temperature (6 K) static NMR-DNP for metalloproteins, proteins in cells, and materials
- Dynamical Diffraction Analysis for 3D Electron Crystallography
- Synthetic biology approaches for bio-orthogonal labeling of circular RNAs
- Break Wave lithotripsy to fragment large kidney stones
Research funding history
10 SBIR/STTR records share this UEI (2017–2024). Reported award amounts total $6,333,111. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services